Degodas 2.5mg Medisun treatment and prevention of osteoporosis (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Ipandronic Acid
Ingredient CPDP Medisun Company

Ingredient

Composition information	Content
Ipandronic Acid	2.5mg

Uses

Indications

Degodas 2.5mg drug indicated and prevented osteoporosis in postmenopausal women.

Pharmacokology

Mechanism of action

Bandronate's effect on bone -based bones based on Hydroxyapatite, which is the substrate of IBANDONAT bone inhibits the cancellation activity and reduces bones and changes bones. In menopause women, the drug reduces the rate of bone change, leading to increased bone mass.

DEGODAS treatment every day reduces signs of bone changes, including C-Termial Telopeptide of Type I Collagen (JCTX) in urine and serum osteocalcin, before menopause.

The changes of bone oil branded oil are recorded after the signs of bone destruction, as expected by the soldiers to naturally destroy the bone and like the bone. Degodas treatment every day reduces UCTX within 1 month after treatment and reduction of osteocalcin within 3 months.

Signs of the lowest -level -based -changing bone changes are about 64% under the boundary after 6 months of treatment and keep stable for 3 years if continued treatment. When stopping treatment, bone cancellation will rise again before treatment in postmenopausal osteoporosis women.

Degodas increases the density of bone minerals and reduces the fracture of the vertebra fracture

Dynamic pharmacokinetics

Absorption of drugs:

IBANDRONAT orally, absorbed at the above digestive tract. The concentration of medication in the blood increases proportional to the dose rising to 50 mg, and does not increase proportional if used above this dose.

After drinking, the blood concentration in the blood peaks after 0.5-2 hours (average 1 hour). Absorption of drugs is reduced by food or drinks (except for filtered water).

IBANDRONAT activity is reduced by up to 90% when used with meals compared to food when hungry.

If taken for 60 minutes before eating, drug activity changes significantly. However, the biological activity and the effect of the drug on the density of bone decrease if food or drink earlier 60 minutes after taking the drug.

Drug distribution:

After absorption, ibandronat quickly attaches to the bone and releases urine. On humans, the drug distribution is at least 90 l, and the absorption concentration into the bone is about 40-50% of the circulation concentration.

IBANDONAT CONTRACT with plasma proteins from 90.0% to 99.5% corresponding to ibandronat concentration from 2-10 ng/l

Metabolism:

ibandronat is not metabolized through the liver and does not inhibit cytochrome P450 enzymes. IBANDRONAT eliminates the kidneys.

Era:

IBANDRONAT when not distributed into the bone will be discharged in the form of unchanged by the kidney (about 50-60% of the concentration absorbed into the blood). IBANDRONAT has not absorbed into the bloodstream will be discharged through the constant form.

Before taking Degodas 2.5mg Medisun treatment and prevention of osteoporosis (3 blisters x 10 tablets)

How to use

to maximize the absorption and effectiveness should take Degodas at least 60 minutes before eating or drinking first of the day or before taking any other oral supplements or supplements, including calcium, antacids, or vitamins.

To promote the transport of drugs into the stomach to reduce the ability to irritate the esophagus, drink degodas with a full glass of water (200-250ml) in a standing or sitting posture. The patient must not stay in 60 minutes after taking Degodas.

Do not eat or drink anything (except for water), or take any other drug at least 60 minutes after drinking Degodas. Degodas should only be taken with water.

Note that some mineral water may contain high calcium concentrations, so it should not be used.

Patients must not chew or suck the tablet because it is at risk of throat ulcers.

Dosage

Adults: Take a tablet of 2.5mg daily in the morning.

No dose adjustment for patients with medium or mild renal impairment.

No dose adjustment for the elderly, or liver failure.

Recommendations on the supplementation of calcium and vitamin D: Patients need to be supplemented with calcium and vitamin D if the diet does not meet sufficiently.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when using overdose?

What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

Unwanted effects when using Degodas 2.5mg that you can meet.

Popular symptoms:

urinary tract: bladder pain, color or cloudy, difficult urine, burning or urination, urination. breasts.

Systemic body: Painful body aches, dizziness, puffiness or swelling of the eyelids, lips, or tongue. Okay:

Digestive: abdominal pain numbness and numbness around the mouth, fingers, or feet, pain, swelling, or numbness in the mouth or jaw.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Degodas 2.5mg contraindications in the following cases:

Patients with a history of peptic ulcer.

Be cautious when using

The adverse digestive reaction ondegodas as well as other oral bisphosphonats drugs, which can cause local irritation to the above digestive tract mucosa.

Because of this irritating properties and the risk of worsening the disease, carefully should be careful when indicating degodas for patients with the above digestive tract problems (such as Barrett esophagus, difficulty swallowing, other esophageal diseases, inflammation or ulcerative ulcer).

Side effects in the esophagus such as esophagitis and esophagitis, sometimes accompanied by hemorrhage and rarely cause stenosis or perforation, this has been reported in patients treated with oral bisphosphonats.

In some cases, patients may be severe to be hospitalized. Therefore, the doctor should be wary of any signs or symptoms of the esophageal reaction and the patient should be instructed to continue to drink degodas and go to the doctor if it is difficult to swallow, swallow pain, pain behind the sternum or heartburn appears or severe.

The risk of severe side effects in the esophagus is common in patients after taking bisphosphonate or those who do not take medicine with sufficient water (200-250ml), and / or patients who continue to use bisphosphonate after detecting suggestions for stimulation of esophagus. In patients with mental disorders that do not comply with the medication guide, the treatment with Degodas should be carefully monitored.

There have been reports on complications of stomach and duodenal ulcer when using bisphosphonate, several cases of serious complications.

However, there is no clinical trial research that has a group of evidence that increases the risk of this complication.

Use drugs in special cases: Do not use degodas for patients with severe renal impairment (creatinine clearance

Reducing blood calcium and mineral metabolism:

Treatment of blood calcium and other disorders of bone and metabolism before starting Degodas treatment.

Supplementing enough calcium and vitamin D is important in all patients to prevent blood calcium.

musculoskeletal pain:

There are cases of bone pain, joints and muscle pain that have been reported after treatment with Degodas and other types of bisphosphonate.

The onset of symptoms changes from one day to a few months after starting to use.

Most patients reduce symptoms after the drug discontinuation. Patients may have pain again during re -treatment. Consider stopping use if serious symptoms.

Jaw bone necrosis:

bone necrosis, mainly in the jawbone, has been reported in patients treated with bisphosphonats. Most cases occur in cancer patients with dental procedures, but in compatibility occurs patients with osteoporosis after menopause or osteoporosis due to other causes.

The known risk factors of bone necrosis include: diagnosis of cancer, combined treatment (for example, chemotherapy, radiation, corticosteroid), and accompanying disease (for example, anemia, coagulation disorders, infections, dental diseases before).

Most cases are told in patients with intravenous bisphosphonate treatment but also some cases occur on oral patients.

For patients with jaw bone necrosis when treated with bisphosphonate, dental surgery can worsen this condition.

For patients requiring the current dental procedure, there is no recommended data whether or not to stop treating bisphosphonate to reduce the risk of jaw bone necrosis.

Clinical assessment of a doctor for treatment will help orient the treatment for each specific case.

Broken under the typical femoral shift and thigh fracture.

Not typical femoral fractures, or minor injuries have been reported in patients treated with bisphosphonat. These fractures can occur anywhere on the thigh bone from the bottom of the small to the convex.

Causes have not been verified, but this fracture also appears in untreated patients with bisphosphonats.

Barefoot fractures often appear when a minor injury or no injury. It can be protected by both sides and many patients with the symptoms in the affected area, usually symptoms of thigh pain, weeks to month before the fracture appears.

Some cases of fractures when the patient is being treated at the same time with glucocorticoid (prednisone ...).

Some patients with a history of bisphosphonate that appear in the thigh or row should suspect that there is no typical fracture.

Patients who are found to have typical fractures should also assess the symptoms and signs of fractures in the opposite limb. Treatment of bisphosphonate should be considered and balanced between benefits and risks in each patient.

Severe kidney failure:

Degodas is not recommended for patients with severe renal failure (clearly clearly

Elderly:

In Degodas research every day treatment of osteoporosis after menopause. There is no difference in effectiveness or safety in elderly patients compared to young people but some older cases may increase sensitivity.

Women during pregnancy and lactation

Because there are no adequate and controlled studies in pregnant women, they do not use this drug for pregnant women.

It is not clear whether degodas secreted in breast milk, so it is not used for breastfeeding women.

The ability to drive and operate machinery

The drug does not cause sleep, so it can be used for drivers and operating machinery

Interactive drug

antacid calcium supplements:

Products containing calcium and positive chemotherapy (aluminum, magnesium, iron) have the effect of absorbing Degodas.

Should take at least 60 minutes before taking the drug containing positive ions of chemotherapy, acid resistance, vitamins.

Aspirin/non-steroid anti-inflammatory drugs (NSAIDs): Because aspirin, nsaids, biphosphonat all cause stomach irritation, should pay attention when combining the use of these drugs.

H2 anti -H2:

When using ranitidin, it increases the biological activity of the Bandronat.

Interaction with other drugs:

biphosphonate has interactive with bone photography. Bandronat's research has not been conducted.

Storage

Leave a cool place, avoid light, temperature below 30⁰C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.